^
CD276 underexpression + EGFR mutation
LUAD
EGFR inhibitor
Sensitive: C3 – Early Trials
World J Surg Oncol - 1 week - (New C3)
EGFR V786M
LUAD
EGFR inhibitor
Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
LMO7-ALK rearrangement
LUAD
crizotinib
Sensitive: C4 – Case Studies
Front Oncol - 1 week - (New C4)
EGFR T790M
LUAD
EGFR inhibitor
Sensitive: C3 – Early Trials
PLoS One - 3 weeks - (New C3)
No biomarker
LUAD
nintedanib
Sensitive: A1 - Approval
PD-L1 underexpression
LUAD
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
LUAD
DP
Sensitive: A2 - Guideline
No biomarker
LUAD
GC
Sensitive: A2 - Guideline
No biomarker
LUAD
cisplatin + pemetrexed
Sensitive: A2 - Guideline
EGFR mutation
LUAD
gefitinib
Sensitive: B - Late Trials
EGFR T790M
LUAD
erlotinib
Sensitive: B - Late Trials
EGFR exon 19 deletion
LUAD
gefitinib
Sensitive: B - Late Trials
EGFR mutation
LUAD
afatinib
Sensitive: B - Late Trials
EGFR exon 19 deletion
LUAD
afatinib
Sensitive: B - Late Trials
EGFR L858R
LUAD
gefitinib
Sensitive: B - Late Trials
EGFR L858R
LUAD
erlotinib
Resistant: B - Late Trials
EGFR T790M
LUAD
gefitinib
Sensitive: B - Late Trials
HER-2 exon 20 insertion + TMB-L + PD-L1 negative
LUAD
Immunotherapy
Sensitive: B - Late Trials
EGFR L858R
LUAD
afatinib
Sensitive: B - Late Trials
EGFR mutation
LUAD
bevacizumab + erlotinib
Sensitive: C1 - Off-label
PD-L1 expression
LUAD
atezolizumab
Sensitive: C1 - Off-label
MET exon 14 mutation
LUAD
tepotinib
Sensitive: C1 - Off-label
EGFR exon 19 deletion
LUAD
osimertinib
Resistant: C1 - Off-label
BRAF V600E
LUAD
trametinib + dabrafenib
Sensitive: C1 - Off-label
ATM mutation
LUAD
olaparib
Sensitive: C1 - Off-label
EGFR T790M
LUAD
osimertinib
Resistant: C1 - Off-label
EGFR L858R
LUAD
osimertinib
Sensitive: C1 - Off-label
EGFR mutation
LUAD
erlotinib
Sensitive: C1 - Off-label
RET fusion
LUAD
pralsetinib
Sensitive: C1 - Off-label
ALK positive
LUAD
lorlatinib
Sensitive: C1 - Off-label
MET exon 14 mutation
LUAD
capmatinib
Sensitive: C1 - Off-label
EGFR L861Q
LUAD
osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
LUAD
bevacizumab
Sensitive: C2 – Inclusion Criteria
KRAS mutation
LUAD
trametinib
Sensitive: C2 – Inclusion Criteria
EGFR S768I
LUAD
erlotinib
Sensitive: C2 – Inclusion Criteria
EGFR mutation
LUAD
osimertinib
Sensitive: C2 – Inclusion Criteria
EGFR wild-type
LUAD
rivoceranib
Sensitive: C2 – Inclusion Criteria
EGFR exon 19 mutation
LUAD
bevacizumab + erlotinib
Sensitive: C3 – Early Trials
EGFR L858R
LUAD
bevacizumab + erlotinib
Sensitive: C3 – Early Trials
EGFR mutation
LUAD
cetuximab + afatinib
Sensitive: C3 – Early Trials
EGFR mutation + PD-L1 overexpression
LUAD
EGFR inhibitor
Resistant: C3 – Early Trials
ROS1 rearrangement
LUAD
crizotinib
Sensitive: C3 – Early Trials
EGFR exon 19 deletion + PD-L1 overexpression
LUAD
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR mutation
LUAD
bevacizumab + afatinib
Sensitive: C3 – Early Trials
EGFR mutation
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR-RAD51 fusion
LUAD
EGFR inhibitor
Resistant: C3 – Early Trials
EGFR exon 18-25 duplication
LUAD
afatinib
Sensitive: C3 – Early Trials
ALK rearrangement
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR T790M
LUAD
bevacizumab + osimertinib
Resistant: C3 – Early Trials
EGFR L861Q
LUAD
afatinib
Sensitive: C3 – Early Trials
HER-2 mutation
LUAD
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
EGFR G719X
LUAD
afatinib
Sensitive: C3 – Early Trials
SNX20 overexpression + PD-L1 overexpression
LUAD
PD1 inhibitor
Sensitive: C3 – Early Trials
PIK3CA mutation + PTEN deletion
LUAD
gefitinib
Sensitive: C3 – Early Trials
TP53 mutation
LUAD
Immunotherapy
Sensitive: C3 – Early Trials
EGFR mutation + KRAS mutation
LUAD
EGFR inhibitor
Resistant: C3 – Early Trials
PIK3CA mutation + PTEN deletion
LUAD
osimertinib
Sensitive: C3 – Early Trials
OGG1 S326C
LUAD
carboplatin + pemetrexed
Sensitive: C3 – Early Trials
MUTYH Q324H
LUAD
carboplatin + pemetrexed
Sensitive: C3 – Early Trials
MUTYH Q324H
LUAD
cisplatin
Sensitive: C3 – Early Trials
OGG1 S326C
LUAD
cisplatin
Sensitive: C3 – Early Trials
EGFR mutation + MDM4 *32C>A
LUAD
gefitinib
Sensitive: C3 – Early Trials
KEAP1 mutation + MSI-L/dMMR
LUAD
Immunotherapy
Resistant: C3 – Early Trials
IFI27 underexpression
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR overexpression
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
PD-L1 overexpression
LUAD
pemetrexed
Sensitive: C3 – Early Trials
ALK positive
LUAD
pemetrexed
Sensitive: C3 – Early Trials
ROS1 rearrangement
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
EGFR exon 21 mutation
LUAD
erlotinib
Sensitive: C3 – Early Trials
EGFR exon 19 mutation
LUAD
erlotinib
Sensitive: C3 – Early Trials
EGFR mutation + PIK3CA mutation
LUAD
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
EGFR mutation + TP53 mutation
LUAD
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
EGFR T790M
LUAD
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
STK11 deletion + KRAS mutation
LUAD
PD-L1 inhibitor
Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation
LUAD
PD-L1 inhibitor
Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation
LUAD
PD1 inhibitor
Sensitive: C3 – Early Trials
STK11 deletion + KRAS mutation
LUAD
PD1 inhibitor
Sensitive: C3 – Early Trials
CD74-NRG1 fusion
LUAD
afatinib
Sensitive: C3 – Early Trials
YBX1 overexpression
LUAD
gefitinib
Resistant: C3 – Early Trials
STK11 mutation
LUAD
Immunotherapy
Resistant: C3 – Early Trials
SMARCA4 mutation
LUAD
Immunotherapy
Resistant: C3 – Early Trials
PBRM1 mutation
LUAD
Immunotherapy
Resistant: C3 – Early Trials
KEAP1 mutation
LUAD
Immunotherapy
Resistant: C3 – Early Trials
PBRM1 mutation + MSI-L/dMMR
LUAD
Immunotherapy
Resistant: C3 – Early Trials
BRAF mutation + TMB-L + MSI-L/dMMR
LUAD
Immunotherapy
Resistant: C3 – Early Trials
PBRM1 mutation + TMB-L + MSI-L/dMMR
LUAD
Immunotherapy
Resistant: C3 – Early Trials
BRAF mutation + MSI-L/dMMR
LUAD
Immunotherapy
Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression
LUAD
afatinib
Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression
LUAD
erlotinib
Resistant: C3 – Early Trials
EGFR mutation + PD-L1 overexpression
LUAD
gefitinib
Resistant: C3 – Early Trials
SDC4-NRG1 fusion
LUAD
afatinib
Sensitive: C3 – Early Trials
HER-2 mutation
LUAD
afatinib
Sensitive: C3 – Early Trials
KRAS mutation
LUAD
gefitinib
Sensitive: C3 – Early Trials
POLD1 C284Y
LUAD
pembrolizumab
Sensitive: C3 – Early Trials
MET D1010N
LUAD
crizotinib
Sensitive: C3 – Early Trials
SCN8A Q225X
LUAD
pembrolizumab
Sensitive: C3 – Early Trials